Literature DB >> 10863026

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

R Kohnken1, K Buerger, R Zinkowski, C Miller, D Kerkman, J DeBernardis, J Shen, H J Möller, P Davies, H Hampel.   

Abstract

A new sandwich ELISA is described which shows specificity for tau phosphorylated at threonine 231 and preferentially reacts with Alzheimer's disease (AD) brain extracts relative to other dementias. This assay was used to analyze 58 antemortem cerebrospinal fluid samples. Twenty-three of 27 AD samples (85% sensitivity) yielded signals greater than the cutoff, while only one of 31 non-AD samples (97% specificity) were greater. This indicates that detection of phosphotau in cerebrospinal fluid with this sandwich ELISA could prove useful in the diagnosis of AD.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10863026     DOI： 10.1016/s0304-3940(00)01178-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  56 in total

1.  CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

Authors:  Norbert Zilka; Miroslava Korenova; Branislav Kovacech; Khalid Iqbal; Michal Novak
Journal:  Acta Neuropathol       Date:  2010-04-09       Impact factor: 17.088

Review 2.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

3.  A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease.

Authors:  Suk Ling Ma; Nelson Leung Sang Tang; Cindy Woon Chi Tam; Victor Wing Cheong Lui; Linda Chiu Wa Lam; Helen Fung Kum Chiu; Jane Ann Driver; Lucia Pastorino; Kun Ping Lu
Journal:  Neurobiol Aging       Date:  2010-06-30       Impact factor: 4.673

4.  Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Terence J O'Brien
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Authors:  Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A Saint Louis; Anders Wallin; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-09-24       Impact factor: 4.673

Review 6.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

Review 7.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

Review 8.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease.

Authors:  Stefani N Thomas; Diane Cripps; Austin J Yang
Journal:  Methods Mol Biol       Date:  2009

10.  Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Authors:  Rilee H Robeson; Andrew M Siegel; Travis Dunckley
Journal:  Biomark Insights       Date:  2008-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.